MARKET DEFINITION

The component of any medication that has the desired health effects is called the active pharmaceutical ingredient (API). The raw materials used to make the APIs have specific strengths and chemical concentrations. Several APIs may act differently or treat various symptoms in some medications, such as combination therapies. Additionally, APIs are used in premium medications that address conditions related to oncology, cardiology, CNS and neurology, orthopedics, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology. The two main categories of APIs are synthetic and natural. Under the process of synthesis, synthetic APIs are further divided into the novel and generic synthetic APIs. Though many small molecule drugs are commercially available on the market, synthetic chemical APIs, also known as small molecules, make up a sizable portion of the pharmaceutical market. Despite the rising demand, there are currently far fewer biologics available than small molecule medications. Therefore, by introducing more cutting-edge products, APIs may be able to develop a more sustainable healthcare system.

MARKET DYNAMICS

The demand for pharmaceutical products is one of the main drivers of the market's growth because of rising awareness and health concerns. Additionally, as pet ownership increases, so does the demand for pet healthcare supplies and medications. Additionally, government assistance through the Scheme for Strengthening of the Pharmaceuticals Industry (SPI) promotes market expansion. The pricing of the products, however, is unusual and erratic, which tends to limit market expansion. Additionally, the use of small molecules by pharmaceutical companies to deliver new therapies has significantly changed due to the development of highly potent active pharmaceutical ingredients (HPAPIs), and it is anticipated that post-pandemic health awareness will rise, opening up lucrative business opportunities.

REPORT SCOPE

The report titled “Global Active Pharmaceutical Ingredient (API) Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Active Pharmaceutical Ingredient (API) market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Active Pharmaceutical Ingredient (API) market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Active Pharmaceutical Ingredient (API) Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION

The Global Active Pharmaceutical Ingredient (API) Market is segmented based on Product Type, Application, Indication, Sales Channel, End Use, and Region. Based on Product Type, the market has been segmented into Synthetic Chemical API, and Natural Chemical API, whereas based on Application, the market comprises Tablets, Capsule, Injectable, Creams, and Others. Based on Indication, the market has been segmented into Communicable Diseases, Diabetes, Cardiovascular Disease, Pain management, Respiratory Diseases, Anti-infective, and Other, whereas, the Sales Channel Segmentation Hospital Pharmacies, Independent Drug Stores, Online Stores, and Others. Furthermore, the End Use Segmentation is bifurcated into Human Treatment, and Animal Treatment.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Active Pharmaceutical Ingredient (API) market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Active Pharmaceutical Ingredient (API) market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Active Pharmaceutical Ingredient (API) market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Active Pharmaceutical Ingredient (API) industry in the past three years.

Key players in the Global Active Pharmaceutical Ingredient (API) Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• Novartis AG
• Pfizer, Inc.
• Bristol-Myers Squibb
• Eli Lilly and Company
• GlaxoSmithKline plc.
• Teva Pharmaceutical Industries Ltd.
• F Hoffmann-La Roche Ltd.
• AstraZeneca
• Merck & Co., Inc.
• Cipla, Inc.
• AbbVie Inc.
• Glenmark Pharmaceutical Ltd.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Reddy’s Laboratories Ltd.
• Aurobindo Pharma

COVID-19 IMPACT ANALYSIS ON GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT (API) MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1. What is the current size of the global Active Pharmaceutical Ingredient (API) market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Active Pharmaceutical Ingredient (API) market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

• The report offers comprehensive data on the Active Pharmaceutical Ingredient (API) market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity

Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Indication
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective

Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Product Type Trends
3.2.2. Application Trends
3.2.3. Indication Trends
3.2.4. Sales Channel Trends
3.2.5. End Use Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Active Pharmaceutical Ingredient (API) Market
3.6. COVID-19 Impact Assessment in Active Pharmaceutical Ingredient (API) Market
3.6.1. Impact Assessment on Global Active Pharmaceutical Ingredient (API) Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4. Global Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
4.1. Global Active Pharmaceutical Ingredient (API) Market Share, By Product Type, 2017 - 2028 (USD Million)
4.1.1. Synthetic Chemical API
4.1.2. Natural Chemical API
 

Chapter 5. Global Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
5.1. Global Active Pharmaceutical Ingredient (API) Market Share, By Application, 2017 - 2028 (USD Million)
5.1.1. Tablets
5.1.2. Capsule
5.1.3. Injectable
5.1.4. Creams
5.1.5. Others

Chapter 6. Global Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
6.1. Global Active Pharmaceutical Ingredient (API) Market Share, By Indication, 2017 - 2028 (USD Million)
6.1.1. Communicable Diseases
6.1.2. Diabetes
6.1.3. Cardiovascular Disease
6.1.4. Pain management
6.1.5. Respiratory Diseases
6.1.6. Anti-infective
6.1.7. Other
 

Chapter 7. Global Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
7.1. Global Active Pharmaceutical Ingredient (API) Market Share, By Sales Channel, 2017 - 2028 (USD Million)
7.1.1. Hospital Pharmacies
7.1.2. Independent Drug Stores
7.1.3. Online Stores
7.1.4. Others

Chapter 8. Global Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
8.1. Global Active Pharmaceutical Ingredient (API) Market Share, By End Use, 2017 - 2028 (USD Million)
8.1.1. Human Treatment
8.1.2. Animal Treatment

Chapter 9. Global Active Pharmaceutical Ingredient (API) Market Overview, By Geography, 2017 - 2028 (USD Million)
9.1. Global Active Pharmaceutical Ingredient (API) Market Share, By Geography, 2017 - 2028 (USD Million)
9.1.1. Market Application and Projections, by Countries, 2017 - 2028 (USD Million)
9.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 10. North America Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. North America Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market Application and projections, 2017 - 2028 (USD Million)
10.1.2. North America Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
10.1.3. North America Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
10.1.4. North America Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
10.1.5. North America Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.1.6. North America Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
10.2. North America Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. U.S. Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. U.S. Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
10.2.1.2. U.S. Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.1.3. U.S. Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.1.4. U.S. Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.1.5. U.S. Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
10.2.2. Canada Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. Canada Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
10.2.2.2. Canada Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.2.3. Canada Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.2.4. Canada Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.2.5. Canada Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
10.2.3. Mexico Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Mexico Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
10.2.3.2. Mexico Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.3.3. Mexico Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.3.4. Mexico Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.3.5. Mexico Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)

Chapter 11. Europe Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Europe Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market Application and projections, 2017 - 2028 (USD Million)
11.1.2. Europe Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.1.3. Europe Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.1.4. Europe Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.1.5. Europe Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.1.6. Europe Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2. Europe Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. Germany Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. Germany Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.1.2. Germany Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.1.3. Germany Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.1.4. Germany Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.1.5. Germany Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2.2. France Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. France Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.2.2. France Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.2.3. France Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.2.4. France Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.2.5. France Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2.3. UK Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. UK Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.3.2. UK Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.3.3. UK Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.3.4. UK Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.3.5. UK Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2.4. Italy Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.4.1. Italy Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.4.2. Italy Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.4.3. Italy Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.4.4. Italy Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.4.5. Italy Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2.5. Spain Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.5.1. Spain Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.5.2. Spain Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.5.3. Spain Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.5.4. Spain Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.5.5. Spain Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2.6. NORDIC Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.6.1. NORDIC Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.6.2. NORDIC Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.6.3. NORDIC Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.6.4. NORDIC Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.6.5. NORDIC Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2.7. Russia and CIS Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.7.1. Russia and CIS Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.7.2. Russia and CIS Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.7.3. Russia and CIS Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.7.4. Russia and CIS Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.7.5. Russia and CIS Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
11.2.8. Rest of Europe Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
11.2.8.1. Rest of Europe Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
11.2.8.2. Rest of Europe Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.8.3. Rest of Europe Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.8.4. Rest of Europe Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.8.5. Rest of Europe Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)

Chapter 12. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market Application and projections, 2017 - 2028 (USD Million)
12.1.2. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.1.3. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.1.4. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.1.5. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.1.6. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
12.2. Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. India Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. India Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.2.1.2. India Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.1.3. India Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.1.4. India Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.1.5. India Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
12.2.2. China Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. China Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.2.2.2. China Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.2.3. China Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.2.4. China Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.2.5. China Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
12.2.3. Japan Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Japan Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.2.3.2. Japan Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.3.3. Japan Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.3.4. Japan Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.3.5. Japan Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
12.2.4. ASEAN Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.2.4.1. ASEAN Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.2.4.2. ASEAN Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.4.3. ASEAN Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.4.4. ASEAN Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.4.5. ASEAN Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
12.2.5. South Korea Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.2.5.1. South Korea Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.2.5.2. South Korea Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.5.3. South Korea Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.5.4. South Korea Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.5.5. South Korea Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
12.2.6. Australia Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.2.6.1. Australia Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.2.6.2. Australia Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.6.3. Australia Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.6.4. Australia Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.6.5. Australia Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
12.2.7. Rest of Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
12.2.7.1. Rest of Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
12.2.7.2. Rest of Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.7.3. Rest of Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.7.4. Rest of Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.7.5. Rest of Asia Pacific Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)

Chapter 13. South America Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
13.1. South America Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
13.1.1. Market Application and projections, 2017 - 2028 (USD Million)
13.1.2. South America Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
13.1.3. South America Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
13.1.4. South America Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
13.1.5. South America Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
13.1.6. South America Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
13.2. South America Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
13.2.1. Brazil Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
13.2.1.1. Brazil Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
13.2.1.2. Brazil Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
13.2.1.3. Brazil Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
13.2.1.4. Brazil Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
13.2.1.5. Brazil Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
13.2.2. Argentina Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
13.2.2.1. Argentina Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
13.2.2.2. Argentina Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
13.2.2.3. Argentina Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
13.2.2.4. Argentina Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
13.2.2.5. Argentina Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
13.2.3. Rest of South America Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
13.2.3.1. Rest of South America Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
13.2.3.2. Rest of South America Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
13.2.3.3. Rest of South America Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
13.2.3.4. Rest of South America Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
13.2.3.5. Rest of South America Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)

Chapter 14. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
14.1. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
14.1.1. Market Application and projections, 2017 - 2028 (USD Million)
14.1.2. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
14.1.3. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
14.1.4. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
14.1.5. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
14.1.6. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
14.2. Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Countries, 2017 - 2028 (USD Million)
14.2.1. GCC Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
14.2.1.1. GCC Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
14.2.1.2. GCC Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
14.2.1.3. GCC Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
14.2.1.4. GCC Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
14.2.1.5. GCC Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
14.2.2. South Africa Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
14.2.2.1. South Africa Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
14.2.2.2. South Africa Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
14.2.2.3. South Africa Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
14.2.2.4. South Africa Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
14.2.2.5. South Africa Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)
14.2.3. Rest of Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, 2017 - 2028 (USD Million)
14.2.3.1. Rest of Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Product Type, 2017 - 2028 (USD Million)
14.2.3.2. Rest of Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Application, 2017 - 2028 (USD Million)
14.2.3.3. Rest of Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Indication, 2017 - 2028 (USD Million)
14.2.3.4. Rest of Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
14.2.3.5. Rest of Middle East & Africa Active Pharmaceutical Ingredient (API) Market Overview, By End Use, 2017 - 2028 (USD Million)

Chapter 15. Competitive Landscape
15.1. Competitive Environment, 2021
15.2. Strategic Framework
15.2.1. Partnership/Collaborations/Agreement
15.2.2. Expansion
15.2.3. Mergers & Acquisitions
15.2.4. New Product Development
 

Chapter 16. Key Vendor Analysis
16.1. Novartis AG
16.1.1. Business Overview
16.1.2. Product Benchmarking
16.1.3. Financial Data
16.1.4. Strategic Overview
16.1.5. Key Developments
16.1.6. SWOT Analysis
16.2. Pfizer, Inc.
16.2.1. Business Overview
16.2.2. Product Benchmarking
16.2.3. Financial Data
16.2.4. Strategic Overview
16.2.5. Key Developments
16.2.6. SWOT Analysis
16.3. Bristol-Myers Squibb
16.3.1. Business Overview
16.3.2. Product Benchmarking
16.3.3. Financial Data
16.3.4. Strategic Overview
16.3.5. Key Developments
16.3.6. SWOT Analysis
16.4. Eli Lilly and Company
16.4.1. Business Overview
16.4.2. Product Benchmarking
16.4.3. Financial Data
16.4.4. Strategic Overview
16.4.5. Key Developments
16.4.6. SWOT Analysis
16.5. GlaxoSmithKline plc.
16.5.1. Business Overview
16.5.2. Product Benchmarking
16.5.3. Financial Data
16.5.4. Strategic Overview
16.5.5. Key Developments
16.5.6. SWOT Analysis
16.6. Teva Pharmaceutical Industries Ltd.
16.6.1. Business Overview
16.6.2. Product Benchmarking
16.6.3. Financial Data
16.6.4. Strategic Overview
16.6.5. Key Developments
16.6.6. SWOT Analysis
16.7. F Hoffmann-La Roche Ltd.
16.7.1. Business Overview
16.7.2. Product Benchmarking
16.7.3. Financial Data
16.7.4. Strategic Overview
16.7.5. Key Developments
16.7.6. SWOT Analysis
16.8. AstraZeneca
16.8.1. Business Overview
16.8.2. Product Benchmarking
16.8.3. Financial Data
16.8.4. Strategic Overview
16.8.5. Key Developments
16.8.6. SWOT Analysis
16.9. Merck & Co., Inc.
16.9.1. Business Overview
16.9.2. Product Benchmarking
16.9.3. Financial Data
16.9.4. Strategic Overview
16.9.5. Key Developments
16.9.6. SWOT Analysis
16.10. Cipla, Inc.
16.10.1. Business Overview
16.10.2. Product Benchmarking
16.10.3. Financial Data
16.10.4. Strategic Overview
16.10.5. Key Developments
16.10.6. SWOT Analysis
16.11. AbbVie Inc.
16.11.1. Business Overview
16.11.2. Product Benchmarking
16.11.3. Financial Data
16.11.4. Strategic Overview
16.11.5. Key Developments
16.11.6. SWOT Analysis
16.12. Glenmark Pharmaceutical Ltd.
16.12.1. Business Overview
16.12.2. Product Benchmarking
16.12.3. Financial Data
16.12.4. Strategic Overview
16.12.5. Key Developments
16.12.6. SWOT Analysis
16.13. Boehringer Ingelheim International GmbH
16.13.1. Business Overview
16.13.2. Product Benchmarking
16.13.3. Financial Data
16.13.4. Strategic Overview
16.13.5. Key Developments
16.13.6. SWOT Analysis
16.14. Viatris Inc.
16.14.1. Business Overview
16.14.2. Product Benchmarking
16.14.3. Financial Data
16.14.4. Strategic Overview
16.14.5. Key Developments
16.14.6. SWOT Analysis
16.15. Dr. Reddy’s Laboratories Ltd.
16.15.1. Business Overview
16.15.2. Product Benchmarking
16.15.3. Financial Data
16.15.4. Strategic Overview
16.15.5. Key Developments
16.15.6. SWOT Analysis
16.16. Aurobindo Pharma
16.16.1. Business Overview
16.16.2. Product Benchmarking
16.16.3. Financial Data
16.16.4. Strategic Overview
16.16.5. Key Developments
16.16.6. SWOT Analysis

Chapter 17. Future Outlook of the Market